Clinical Trials Logo

Toxemia clinical trials

View clinical trials related to Toxemia.

Filter by:

NCT ID: NCT04304235 Completed - Sepsis Clinical Trials

Paediatric Rapid Sepsis Trigger (PRST) Tool

PRST
Start date: April 27, 2020
Phase: N/A
Study type: Interventional

Sepsis is the leading cause of death and disability in children, every hour of delay in treatment is associated with greater organ damage and ultimately death. The challenges, especially in poor countries, are the delays in diagnosis and the inability to identify children in urgent need of treatment.To circumvent these challenges, we propose the development and clinical evaluation of a trigger tool that will reduce the time to diagnosis and prompt the timely initiation of life-saving treatment. The key innovations are 1) a data-driven approach to rapid diagnosis of sepsis severity and 2) a low- cost digital tagging system to track the time to treatment. The tool will require minimal cost, clinical expertise and training or time to use. The tool will identify high risk children and reduce time to treatment. The digital platform (mobile device and dashboard) will create a low-cost, highly scalable solution for children with sepsis.

NCT ID: NCT04303871 Completed - Clinical trials for Hypertension in Pregnancy

Invasive Versus Non-invasive Assessment of Blood Pressure in Hypertensive Disorders of Pregnancy

Start date: December 1, 2018
Phase: N/A
Study type: Interventional

Hypertensive disorders of pregnancy are important causes of maternal morbidity and mortality worldwide. Hypertension is one of the most commonly reported health conditions among pregnant women and complicates 5-10% of all pregnancies.(Martin et al., 2009) (Wagner et al., 2007) The measurement of central BP in hypertensive patients became more important because of its predictive value for cardiovascular events. Direct intra-arterial readings are considered to be the gold standard method for blood pressure measurement but because arterial cannulation is associated with risks, alternative non-invasive blood pressure measurements may be used. (Araghi et al., 2006) In our study, the investigator aimed to assess the accuracy of non-invasive central blood pressure by oscillometric automated device (Mobil O graph) in comparison to the invasive blood pressure measurement by arterial cannulation in patients with hypertensive disorders in pregnancy. the investigators enrolled 100 pregnant women and 10 healthy non-pregnant women as a control group, central blood pressure was measured invasively by arterial cannula and non-invasively by oscillometric automated device (Mobil O Graph). the investigatorshave found a high correlation between non-invasive central blood pressure measurements and invasively measured both systolic (r 0.968, p=0.000) and diastolic (r 0.687, p=0.000).

NCT ID: NCT04292431 Completed - Sepsis Clinical Trials

Leukocyte MOrphology and CORticosteroids Response in SEPtic Patients (MOCORSEP)

MOCORSEP
Start date: November 1, 2019
Phase:
Study type: Observational [Patient Registry]

Non-interventional, prospective, monocentric study on the exploration of leukocyte morphological parameters according to the infectious condition and response to corticosteroid therapy of septic patients.

NCT ID: NCT04291508 Completed - Sepsis Clinical Trials

Acetaminophen and Ascorbate in Sepsis: Targeted Therapy to Enhance Recovery

ASTER
Start date: October 13, 2021
Phase: Phase 2
Study type: Interventional

Prospective multi-center phase 2b randomized placebo-controlled double-blinded interventional platform trial of two different pharmacologic therapies (intravenous Vitamin C or intravenous Acetaminophen) for patients with sepsis-induced hypotension or respiratory failure.

NCT ID: NCT04291417 Completed - Sepsis Clinical Trials

Sepsis Post Market Observational Study and Potential Reduction of Time to Antibiotics - Baylor S&W

Start date: November 20, 2019
Phase:
Study type: Observational

The purpose of this study is to demonstrate that addition of the Monocyte Width Distribution (MDW) parameter to current standard of care improves a clinician's ability to recognize sepsis in the Emergency Department, resulting in earlier decision to administer antibiotics from time of ED presentation for sepsis patients (simulated primary endpoint), with concomitant reductions in length of stay and in-hospital mortality for those patients (secondary endpoints).

NCT ID: NCT04261621 Completed - Sepsis Clinical Trials

Early Identification of SEPsis SIGNs in Emergency Department

SepSIGN
Start date: July 6, 2020
Phase:
Study type: Observational

Objective of SepSIGN project is to validate biomarkers able to predict the clinical worsening of patients freshly admitted at Emergency Department. Targeted population is adult patients, freshly admitted at ED, with a suspected or confirmed infection.

NCT ID: NCT04227652 Completed - Sepsis Clinical Trials

Control of Fever in Septic Patients

COVERSEP
Start date: September 3, 2013
Phase: N/A
Study type: Interventional

The benefits of fever treatment in critically ill patients remains unclear. The aim of the prospective, randomized clinical trial was to verify the hypothesis that the administration of ibuprofen in order to decrease the fever in septic patients without limited cardiorespiratory reserve leads to decreasing their prognosis.

NCT ID: NCT04226430 Completed - Sepsis Clinical Trials

Effect of Cytosorb on Blood Levels of Inflammatory Biomarkers of Sepsis.

Start date: June 1, 2016
Phase:
Study type: Observational [Patient Registry]

Background: There is still an evident need for useful biomarkers and effective therapeutic approaches regarding the challenging management of sepsis. The aim of the study is to evaluate the effect of each Cytosorb hemoadsorption therapy course on blood levels of inflammatory biomarkers of sepsis including endocan, copeptin, interleukin-6, procalcitonin, C-reactive protein.

NCT ID: NCT04216459 Completed - Sepsis Clinical Trials

Effect of Anti-inflammatory and Anti-microbial Co-supplementations in Traumatic ICU Patients at High Risk of Sepsis

DrNoha-ICU
Start date: February 18, 2020
Phase: N/A
Study type: Interventional

The occurrence of sepsis in trauma patients is a very serious complication. Identifying trauma patients at high risk of sepsis was not revealed in the latest surviving sepsis campaign in 2016. Several biomarkers have been proposed for early prediction of sepsis in trauma patients as leukocyte anti sedimentation rate (LAR) and the proinflammatory cytokine monocyte chemo attractant protein-1 (MCP-1). Sepsis prophylaxis before occurrence of multi-organ failure still represents a major challenge. Vitamin D and probiotics have antimicrobial, anti-inflammatory and gut microbiota immune modulatory properties.Little is known about the effect of vitamin D and probiotics co-supplementation on the inflammatory response in trauma patients at high risk of sepsis. Another promising strategy is the use of vitamin C in addition to thiamine. Trauma is associated with increased oxidative stress and vitamin C deficiency. High dose vitamin C is required to restore oxidant-antioxidant balance. Vitamin C and thiamine have shown promising results in treatment of sepsis. Vitamin C possesses anti-inflammatory, endothelial protective and anti-microbial effects. Thiamine is the precursor of thiamine pyrophosphate (TPP), a key enzyme in Krebs cycle.

NCT ID: NCT04214743 Completed - Sepsis Clinical Trials

Ocular Microvascular Changes in Patients With Sepsis

Start date: January 2, 2018
Phase:
Study type: Observational

This study evaluates differences in the ocular microcirculation between septic patients and healthy subjects and the course of ocular microvasculature in survivors and non-survivors over a 24 hours period of time in septic patients